Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Anticoagulants is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention MCI (Mild Cognitive Impairment), all published on March 18, 2026.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Anticoagulants is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention MCI (Mild Cognitive Impairment), all published on March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MCI (Mild Cognitive Impairment). Shared-story counts are live from our verified record — not editorial picks.
Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
MCI (Mild Cognitive Impairment) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
